Sarcopenia or skeletal muscle loss is a frequent, potentially reversible complication in cirrhosis that adversely affects clinical outcomes. Hyperammonemia is a consistent abnormality in cirrhosis that results in impaired skeletal muscle protein synthesis and breakdown (proteostasis). Despite the availability of effective ammonia-lowering therapies, whether lowering ammonia restores proteostasis and increases muscle mass is unknown. Myotube diameter, protein synthesis, and molecular responses in C2C12 murine myotubes to withdrawal of ammonium acetate following 24-hour exposure to 10 mM ammonium acetate were complemented by in vivo studies in the hyperammonemic portacaval anastomosis rat and shamoperated, pair-fed Sprague-Dawley rats treated with ammonia-lowering therapy by L-ornithine L-aspartate and rifaximin orally for 4 weeks. We observed reduced myotube diameter, impaired protein synthesis, and increased autophagy flux in response to hyperammonemia, which were partially reversed following 24-hour and 48-hour withdrawal of ammonium acetate. Consistently, 4 weeks of ammonia-lowering therapy resulted in significant lowering of blood and skeletal muscle ammonia, increase in lean body mass, improved grip strength, higher skeletal muscle mass and diameter, and an increase in type 2 fibers in treated compared to untreated portacaval anastomosis rats. The increased skeletal muscle myostatin expression, reduced mammalian target of rapamycin complex 1 function, and hyperammonemic stress response including autophagy markers normally found in portacaval anastomosis rats were reversed by treatment with ammonia-lowering therapy. Despite significant improvement, molecular and functional readouts were not completely reversed by ammonialowering measures. Conclusion: Ammonia-lowering therapy results in improvement in skeletal muscle phenotype and function and molecular perturbations of hyperammonemia; these preclinical studies complement previous studies on ammonia-induced skeletal muscle loss and lay the foundation for prolonged ammonia-lowering therapy to reverse sarcopenia of cirrhosis. (HEPATOLOGY 2017;65:2045-2058. S arcopenia or loss of skeletal muscle mass is a frequent complication of cirrhosis, advanced heart failure, and chronic lung disease that adversely impacts outcomes.
S arcopenia or loss of skeletal muscle mass is a frequent complication of cirrhosis, advanced heart failure, and chronic lung disease that adversely impacts outcomes. (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) Despite the high clinical significance, there are limited data on the mechanisms of sarcopenia and consequently a lack of effective therapies. (3) Hyperammonemia is a consistent abnormality in cirrhosis due to impaired ureagenesis capacity and portosystemic shunting. (13) (14) (15) Skeletal muscle mass is maintained by proteostasis, a cellular homeostatic process that includes protein synthesis, folding, trafficking, and breakdown. We and others have reported that hyperammonemia impairs skeletal muscle proteostasis by decreased protein synthesis and increased autophagy with consequent sarcopenia. (16) (17) (18) (19) Skeletal muscle hyperammonemia results in transcriptional upregulation of myostatin. Increased expression of myostatin, a transforming growth factor beta superfamily member, contributes to impaired mammalian target of rapamycin complex 1 (mTORC1) signaling and consequent reduction in muscle protein synthesis. (20, 21) Additionally, phosphorylation of eukaryotic initiation factor 2-alpha (eIF2a) also contributes to impaired protein synthesis and sarcopenia. (17, 22, 23) Our previous studies have shown that during hyperammonemia both impaired mTORC1 signaling and increased eIF2a phosphorylation impair skeletal muscle protein synthesis. (17, 24) Although hyperammonemia impairs proteostasis, it is not known if lowering ammonia will reverse skeletal muscle molecular and metabolic perturbations and consequent sarcopenia. Ammonia-lowering strategies have been used in preclinical and clinical studies to treat hepatic encephalopathy, a recognized consequence of hyperammonemia. (25) However, there are no reports of skeletal muscle responses to ammonialowering therapy. Of the ammonia-lowering agents used in clinical practice, lactulose therapy is difficult to monitor in animals, and hence, a combination rifaximin by gavage and L-ornithine L-aspartate (LOLA) in the drinking water was used. Rifaximin and LOLA have been reported in rats to lower ammonia and reverse the cerebral effects of hyperammonemia. (26, 27) Despite compelling evidence that hyperammonemia induces skeletal muscle metabolic and molecular perturbations, (16, 17, 19) it is not known if lowering ammonia will reverse these responses and consequent sarcopenia. Current options to reverse sarcopenia have focused on nutritional and amino acid supplementation, with limited benefits. (28) There are no published studies on the effects of ammonia-lowering therapies on body composition or skeletal muscle responses. In brain tissue, ammonia accumulates in cirrhosis and backflux (reversed transfer) from the brain into circulation has been reported, (29) but whether ammonia-lowering treatment results in reduction in muscle tissue concentrations and consequent reversal in molecular and functional perturbations is not known. In liver disease, muscle uptake of ammonia is increased (30, 31) with molecular and metabolic perturbations. (16, 19) However, after liver transplantation that reverses the metabolic and hormonal perturbations of cirrhosis, sarcopenia does not reverse and may actually worsen. (4) These observations suggest that the effects of ammonia on skeletal muscle may be irreversible although it is possible that other factors, including the use of mTORC1 and calcineurin inhibitors after transplantation, may replace hyperammonemia as mediators of sarcopenia after transplantation. (3) The present studies were performed initially in vitro in murine myotubes exposed to hyperammonemia followed by withdrawal of ammonia to specifically determine if the responses were indeed reversible. Studies were then performed in the portacaval anastomosis (PCA) rat, a model of sarcopenia in hyperammonemia via surgical portosystemic shunting. (20, 32, 33) 
Materials and Methods

IN VITRO RESPONSES OF MYOTUBES TO AMMONIA WITHDRAWAL
Murine C2C12 myoblasts (ATCC, Manassas, VA) were grown to confluence in proliferation medium (Dulbecco's modified Eagle's medium with 10% fetal bovine serum), followed by 48-hour differentiation in Dulbecco's modified Eagle's medium with 2% horse serum. (34) Differentiated myotubes exposed to 10 mM ammonium acetate for 24 hours were used as reported. (16, 19) For the withdrawal experiments, myotubes were treated with ammonium acetate for 24 hours, followed by removal and replacement with fresh differentiation medium for specified times. Myotube diameter was measured as described by us (16) from at least 100 myotubes from four independent replicate
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plates, and data are expressed as percentage of untreated controls. Protein synthesis was quantified using a puromycin incorporation assay. (17) For signaling responses, cells were lysed, protein was quantified by the bicinchoninic acid assay, and immunoblots for myostatin, total and phosphorylated eIF2a and eIF2a kinase (general control non-derepressible 2 [GCN2]), adenosine monophosphate-activated protein kinase (AMPK), mTORC1 and its targets, p70S6 kinase, ribosomal S6 protein, expression of autophagy markers, LC3 lipidation, and p62 as described. (17) Autophagy flux was determined using the lysosomal inhibitor chloroquin at 25 lM as described. (35) IN VIVO RESPONSE TO AMMONIA-LOWERING THERAPY Postpubertal male Sprague-Dawley rats aged 9 weeks, with either end-to-side PCA or sham surgery, were obtained from Charles River Inc. (Wilmington, MA). Animals were housed individually in a 12-hour light/dark cycle as described. (32) Both groups of animals were fed standard rat chow (Harland Teklad rodent chow 8604; 24.5% protein, 4.4% fat, 3.93 kcal Á g -1 ), with the PCA rats being fed ad libitum and the shamoperated rats being pair-fed (SO) as described. (20) Food and water intake were measured daily. Body weight, body composition measured by total body electrical conductivity, and grip strength were measured weekly as described (20, 33) until euthanasia on the study day. Rifaximin (50 mg Á kg
) in 1 mL of drinking water was administered by gavage daily for 28 days. LOLA was added to the drinking water, and the concentration was adjusted to deliver an amount of 2 g Á kg
. This dose and route of rifaximin and LOLA have been reported to lower blood ammonia in rats. (26, 27) The combination treatment with rifaximin and LOLA (r-LOLA) was started at 48 hours after surgery. At the end of 28 days, on the night before the study day, food but not water was withdrawn to ensure uniform duration of the postabsorptive phase in all animals. Animals were consistently euthanized between 10 AM and 11 AM to avoid circadian alterations in proteostasis in eight animals in each group.
Protein Synthesis In Vivo
A flooding dose of sterile L-[ring-D 5 ]-phenylalanine (D 5 Phe; 300 mM Á kg -1 ) was injected intraperitoneally, and 30 minutes later, rats were euthanized by intraperitoneal pentobarbitone injection. Enrichment of D 5 Phe was quantified in the cytosol and bound to protein by liquid chromatography mass spectrometry/mass spectrometry as described. (24) In brief, muscle tissue was homogenized; deproteinized in 250 lL 0.098 M trichloroacetic acid, containing 0.1-g glass beads using a mini-Bead Beater (Biospec Products, Bartlesville, OK) for 30 seconds; and then centrifuged at 8,000g at 48C for 5 minutes. The protein pellet was then washed 3 times with 0.3 M trichloroacetic acid, and proteins were hydrolyzed with 1 mL 6N hydrochloride solution at 1008C for 24 hours. After adding 5 mL high-performance liquid chromatography-grade water, samples were dried down with a vacuum concentrator (SpeedVac; Thermo Scientific, Waltham, MA). Samples were then dissolved in 20 lL water/mg wet tissue weight and centrifuged at 50,000g 48C for 5 minutes, and 20 lL of the supernatant was used for the tracer/tracee analyses of protein-bound phenylalanine by liquid chromatography/mass spectrometry/ mass spectrometry.
Samples and enriched standards with tracer/tracee ratios of D 5 Phe in expected ranges (calibration curve for tracer/tracee measurements) were derivatized using 9-fluorenylmethoxycarbonyl. Electrospray triplequadrupole tandem mass spectrometry in multiple reaction monitoring mode was used for detections. The area under the curve of a mass signal was used to calculate tracer/tracee using the D 5 Phe calibration curve. Quality control of the 9-fluorenylmethoxycarbonyl derivatization procedure was done using the mass signal of the
The fractional synthesis rate of protein synthesis was calculated by the formula MPE bound =ðMPE free 3tÞ where MPE bound is the mole percent excess of D 5 Phe in the muscle protein, MPE free is the enrichment in the cytosol, and t is the exact time in hours, and expressed as percent per hour. Absolute synthesis rate was calculated as the product of the fractional protein synthesis rate and the total muscle protein content, as described, (20) and expressed as milligrams per hour. The total protein in the skeletal muscle was measured using the BioRad DC assay (Hercules, CA). Food efficiency (D weight Á g food intake -1 ) was calculated as described. (20) Protein Synthesis In Vitro
Puromycin incorporation was used to quantify protein synthesis in C2C12 myotubes by incubating the cells following treatment with ammonium acetate or medium alone, adding 1 lM puromycin in the final 30 minutes, and performing immunoblots for puromycin incorporation as described. (17) QUANTITATIVE ANALYSES Ammonia concentrations were quantified using methods standardized in our laboratory. (16) Plasma free amino acids were quantified using ion-exchange chromatography (L-8900; Hitachi, Tokyo, Japan) with a postcolumn ninhydrin reaction (Wako). (24) Cryosections of gastrocnemius muscle were stained, and the minimal internal diameter, area on hematoxylin eosin stain, and ratio of type 2/type 1 fibers on adenosine triphosphatase stain were quantified as described. (36) The percentage of fibrosis/muscle fiber areas was also determined. , phosphoribosomal s6 protein Ser240/244 , and phospho-4E binding protein 1 Thr37/45 . Activation of Akt, the canonical mTORC1 activator, and AMPK, the classical inhibitor of mTORC1, was examined by immunoblot assay for phospho-AMPK Thr172 .
Signaling Responses
Autophagy
Autophagy markers were quantified by immunoblots for LC3 lipidation and Beclin1 and p62 expression in protein extracts as reported. (19) Autophagy flux was quantified by LC3 lipidation with and without chloroquin as described. (35) 
Immunoblots
Immunoblots on protein extracts were performed using protocols established in our laboratories as described earlier. In brief, electrophoresis of 30 lg protein was performed on an 8% trishydroxymethylaminomethane glycine gel except for LC3 lipidation, where a 12% gel was used; electrotransferred to polyvinylidene fluoride membrane; and incubated with primary followed by secondary antibody in the appropriate Lower myotube diameter was partially reversed at 24 hours and completely reversed at 48 hours after withdrawal of ammonia. All experiments from at least 100 myotubes from four independent plates of cells. Data expressed as mean 6 standard deviation. *P < 0.05, ***P < 0.001 versus untreated control. (C,D) Partial recovery of protein synthesis in myotube following ammonia withdrawal. Representative immunoblots and densitometry from at least three biological replicates of puromycin incorporation in C2C12 myotubes treated with 10 mM ammonium acetate, following withdrawal of ammonium acetate and untreated controls. Data expressed as mean 6 standard deviation from experiments in at least three biological replicates. *P < 0.05, **P < 0.01, ***P < 0.001. Abbreviations: AmAc, ammonium acetate; A.U., arbitrary units; CTL, control; WD, withdrawal.
FIG. 2. Recovery of signaling responses following ammonia withdrawal in myotubes. (A)
Representative immunoblots and densitometry of myostatin, phospho-AMPK, and its target acetyl coenzyme A carboxylase in C2C12 myotubes treated with 10 mM ammonium acetate and following replacement with ammonia-free differentiation. (B) Representative immunoblots and densitometry of eIF2a kinase phospho-GCN2 and phospho-eIF2a in C2C12 myotubes during hyperammonemia and following replacement of medium with ammonia-free differentiation medium for 24 and 48 hours. Data show near complete reversal of ammonia-induced alterations in activation of GCN2 and phosphorylation of eIF2a. (C) Representative immunoblots and densitometry of mTORC1 signaling (phosphorylation of mTORC1, P70S6 kinase, ribosomal S6 protein, and 4EBP1). Data show that ammonia impairs mTORC1 activation and signaling that is partially reversed after ammonia withdrawal. (D) Representative immunoblots and densitometry show that increased LC3 lipidation and lower P62 expression following exposure to 10 mM ammonium acetate were reversed after 24 and 48 hours of ammonia withdrawal. All experiments were done in three biological replicates, and all data are shown as mean 6 standard deviation. *P < 0.05, ***P < 0.001 versus untreated controls.
† P < 0.05 versus 24-hour ammonium acetate; ¶ P < 0.05 versus 24-hour withdrawal group. Abbreviations: ACC, acetyl coenzyme A carboxylase; AmAc, ammonium acetate; A.U., arbitrary units; MSTN, myostatin; p-, phosphorylated; WD, withdrawal. dilutions; blots were then developed, followed by densitometry of the blots using Image J. (32) STATISTICAL ANALYSES
All cellular experimental data were generated from at least three biologically independent experiments. Animal data were obtained from eight animals in each group. Data were expressed as mean 6 standard error of the mean, and means were compared using analysis of variance with Bonferroni post hoc analyses for quantitative data that were normally distributed and the Kruskal-Wallis test for skewed data.
All studies were approved by the Institutional Animal Care and Use Committee at the Cleveland Clinic.
Results
IN VITRO RESPONSES TO AMMONIA WITHDRAWAL FOLLOWING HYPERAMMONEMIA
Myotube diameter was significantly lower in response to hyperammonemia, and following withdrawal of ammonia, there was partial recovery by 24 hours and further increases in myotube diameter and area at 48-hour withdrawal (Fig. 1A,B) . Global protein synthesis was significantly lower following 24 hours of hyperammonemia in myotubes (Fig. 1C,D) . Interestingly, ammonia withdrawal for 24 hours resulted in partial recovery of protein synthesis, and 48-hour withdrawal resulted in a further increase in hyperammonemia-induced impaired protein synthesis in myotubes. Expression of myostatin, a molecular mediator of the signaling responses during hyperammonemia, was increased and reversed by ammonia withdrawal (Fig. 2A) . Phosphorylation of global protein synthesis regulatory protein eIF2a was increased in response to hyperammonemia and reversed following withdrawal (Fig. 2B) . Consistently, phosphorylation of mTORC1 and its downstream signaling targets, p70S6K and ribosomal S6 protein phosphorylation, also recovered nearly completely after 24 hours of ammonia withdrawal (Fig. 2C) . Autophagy marker LC3 lipidation was increased and p62 expression decreased during hyperammonemia, and these perturbations were reversed by ammonia withdrawal at 24 and 48 hours (Fig. 2D) . Autophagy flux was increased during hyperammonemia and reversed at 24 and 48 hours of ammonia withdrawal (Supporting Fig. S1 ).
IN VIVO RESPONSES TO AMMONIA-LOWERING THERAPY IN HYPERAMMONEMIC PCA RATS
Body weight, lean body mass, and grip strength of PCA and SO rats in the vehicle only and ammonialowering therapy groups are shown in Fig. 3A,B and Table 1 . Following the first week, PCA rats had significantly lower body weight, lean body mass, and grip strength compared with SO rats. Lean body mass and grip strength were significantly higher (P < 0.010) in PCA rats treated with r-LOLA compared to vehicle alone-treated animals. In SO rats, no significant effect of r-LOLA was noted compared to the vehicle-treated group. Organ weights in the different groups are shown in Table 2 . Liver, testes, spleen, and fat mass were significantly lower in PCA rats treated with vehicle compared to SO rats. In response to ammonialowering therapy, only muscle mass was higher than in untreated PCA rats. No significant differences were noted in other organ weights in response to r-LOLA in PCA rats.
FIG. 3.
Lowering ammonia in the PCA rat reverses sarcopenia. (A,B) Change in body weight and lean body mass in PCA and SO rats treated with vehicle alone or ammonia-lowering therapy with r-LOLA. Significantly lower whole-body mass in PCA rats treated with vehicle alone was partially reversed after 4 weeks of r-LOLA therapy, while no effect was observed in SO rats. **P < 0.01, ***P < 0.001 versus SO rats; ¶ P < 0.05 versus PCA r-LOLA; W P < 0.01, U P < 0.001 versus PCA r-LOLA. (C) Representative photomicrographs of hematoxylin eosin-stained cryosections of gastrocnemius muscle of from PCA and SO rats treated with vehicle alone or ammonia-lowering therapy with r-LOLA. Mean minimum internal diameter and mean area of the muscle fibers expressed as percentage of SO controls treated with vehicle alone showed reduction in muscle fiber size that was partially reversed by r-LOLA treatment PCA rats for 4 weeks. *P < 0.05, **P < 0.01, ***P < 0.001. (D) Representative photomicrographs of cryosections of gastrocnemius muscle showing fiber type identification using adenosine triphosphatase staining at pH 10. Lower ratio of type 2/type 1 fiber numbers was observed in PCA rats treated with vehicle compared to SO rats. r-LOLA treatment for 4 week reversed the reduction in type 2/type 1 ratio. *P < 0.05, **P < 0.01, ***P < 0.001. (E) Representative photomicrographs of cryosections of gastrocnemius muscle from PCA and SO rats treated with vehicle alone and r-LOLA showed no increase in fibrosis. All experiments in n 5 8 animals in each group. Histomorphometry from at least 50 fibers per muscle from each animal in each group. All data mean 6 standard deviation. r-LOLA orally for 28 days. Abbreviations: LBM, lean body mass; V, vehicle.
Muscle mass and fiber diameter were significantly lower (P < 0.001) in PCA compared to SO rats in the vehicle-treated group (Fig. 3C) . Muscle mass and fiber diameter were greater in r-LOLA-treated PCA rats compared to those treated with vehicle alone (P < 0.01) but were less than values in SO rats (P < 0.05). In SO rats, r-LOLA did not significantly alter muscle mass or fiber diameter. As reported, (36) PCA rats treated with vehicle had a lower percentage of type 2/ type 1 fibers compared to SO rats (P < 0.001) and treatment with r-LOLA partially reversed this phenotype in the PCA rat muscle fiber type (Fig. 3D) . Reduction in fiber size in the hyperammonemic PCA rat was not accompanied by alterations in muscle fibrosis (Fig. 3E) .
Plasma and muscle ammonia concentrations were significantly higher in vehicle-treated PCA rats compared to the other groups (Fig. 4A,B) . r-LOLA treatment resulted in lower plasma and muscle ammonia concentrations. However, muscle ammonia concentrations in r-LOLA-treated PCA rats remained higher than those in SO rats, showing that 28 days of treatment did not completely reverse hyperammonemia of portosystemic shunting. In SO rats, r-LOLA did not lower ammonia concentrations. Amino acid concentrations in plasma and muscle tissue are shown in Supporting Tables S1 and S2. Plasma branched chain amino acids were lower in PCA than SO rats, and in response to r-LOLA there was an increase in branched chain amino acids in PCA rats.
Skeletal muscle fractional and absolute protein synthesis rates in the gastrocnemius muscle were quantified using plasma and intracellular precursor pools and were similar ( Fig. 4C ; Supporting Table S3 ). Both fractional and absolute protein synthesis rates were significantly lower in PCA compared to SO rats. In response to r-LOLA, protein synthesis rates increased in PCA rats but did not show any significant change in the SO group. Muscle expression of myostatin was increased in PCA rats treated with vehicle alone, while those treated with ammonia-lowering therapy showed reversal of myostatin expression and downstream responses. These observations were consistent with the food efficiency in the various groups (Supporting Table S3 ).
Signaling responses in the mTORC1, eIF2a, and autophagy pathway components were quantified by immunoblots and showed that impaired mTORC1 signaling increased phosphorylation of eIF2a and expression of autophagy markers were reversed after ammonia lowering for 28 days (Fig. 5A-D) . 
Discussion
Hyperammonemia is a mediator of the liver-muscle axis and impairs proteostasis due to impaired protein synthesis and increased autophagy. (16, 17, 19) Ammonialowering therapies have been used extensively in the treatment of hepatic encephalopathy, (25) but the effects of this treatment on skeletal muscle proteostasis and muscle mass are not known. The phenotype of lower myotube diameter, metabolic response with lower protein synthesis, and altered signaling responses due to hyperammonemia was significantly reversed by ammonia withdrawal in a time-dependent manner. The physiological relevance of this was noted in hyperammonemic PCA rats that had lesser gain in body weight and lean body mass with lower muscle mass and grip strength compared to SO control rats. Skeletal muscle from PCA rats had greater expression of myostatin; increased phosphorylation of eIF2a, a translational repressor; decreased mTORC1 signaling; and higher expression of autophagy markers compared to SO rats. Therapy with r-LOLA lowered plasma and muscle ammonia concentrations in vivo. Ammonia lowering resulted in partial recovery of the muscle phenotype in PCA rats without significant alteration in other organ weights. Finally, cellular signaling responses, increased myostatin expression and autophagy markers, and the hyperammonemic stress response in the muscle of PCA rats were significantly reversed by ammonialowering therapy.
Whereas the adverse effects of hyperammonemia on skeletal muscle have been reported, (20, 32, 33, 37) we show that ammonia lowering is a potential therapy for sarcopenia by partially reversing the phenotype as well as the molecular and functional perturbations of hyperammonemia in PCA rats. In SO control rats with normal liver function and absence of hyperammonemia, ammonia-lowering treatment, expectedly, did not alter the phenotype, muscle protein synthesis, or molecular markers. Although liver and testes weights were lower   FIG. 4 . Therapy effectively lowered plasma and muscle ammonia concentrations and reversed impaired muscle protein synthesis in PCA rats. (A) Elevated plasma ammonia in vehicle-treated PCA rats lowered after r-LOLA therapy. Nonsignificant reduction in plasma ammonia in SO rats treated with r-LOLA. (B) Elevated skeletal muscle ammonia in vehicletreated PCA rats lowered but remained higher than that in SO rat gastrocnemius muscle. (C) Fractional synthesis rate in vehicle-treated PCA rats was significantly lower than that in SO rats. Ammonialowering therapy with r-LOLA partially reversed this reduction in protein synthesis rate. *P < 0.05, **P < 0.01, ***P < 0.001. n 5 8 animals in each group. All data mean 6 standard deviation. r-LOLA orally for 28 days. Abbreviation: FSR, fractional synthesis rate.
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HEPATOLOGY, June 2017 in PCA rats, unlike the partial recovery of muscle mass and strength, other organ weights did not change in response to ammonia-lowering effects, suggesting that hyperammonemia altered the phenotype and induced a cellular stress response in the skeletal muscle and that these effects are reversible with prolonged therapy. These studies are of high clinical relevance because of previous concerns that the reduced muscle mass in cirrhosis, believed to be due to increased muscle ammonia, is not reversed with normalization of ammonia metabolism following liver transplantation. (4, 16) We show that using an aggressive ammonia-lowering strategy, muscle phenotype and lean body mass improved significantly in hyperammonemic PCA rats. Our complementary in vitro ammonia-withdrawal studies in myotubes also showed that the reduced myotube diameter significantly improved but did not completely normalize following ammonia withdrawal. Because ammonia-lowering therapies are clinically approved in patients with cirrhosis, these observations suggest that such treatment has the potential to reverse sarcopenia in cirrhosis.
Our studies also provide evidence that ammonialowering measures reduce skeletal muscle concentrations of ammonia. Our data are consistent with those in previous reports (20, 36) that muscle and plasma ammonia concentrations were significantly higher in PCA than in SO rats. In the present study, we used the combination r-LOLA because the two interventions have different mechanisms of action (26, 27) and we expected a robust ammonia-lowering effect. However, peripheral plasma ammonia concentrations decreased significantly but did not reach control values. Muscle ammonia concentrations were also decreased significantly with therapy in PCA rats but remained higher than those in the muscles of SO control rats. These data are consistent with previous data that ammonialowering treatments do not completely normalize blood or cerebrospinal fluid ammonia concentrations. (38) (39) (40) It is possible that other measures, including ornithine phenylacetate and cell-permeable esters of a-ketoglutarate, may be more effective at lowering ammonia but are not available for routine use. (41) Whereas backflux of ammonia has been reported in the brain, (29) we report a reduction in muscle ammonia concentrations in a model of prolonged hyperammonemia following long-term ammonia-lowering therapy. Potential mechanisms for incomplete reduction of tissue ammonia concentrations include the continued increased muscle uptake of ammonia in the presence of portosystemic shunting, the need for even longer durations of therapy in the presence of persistent disease, and the increased expression of ammonia transporters in the muscle during hyperammonemia. (42) Even though muscle concentrations of ammonia were not completely reversed following 28-day therapy, it is possible that prolonged therapy may be needed to lower tissue ammonia content, which may require studies that focus on ammonia transport function.
Ammonia results in alterations in circulating branched chain amino acid concentrations. (43) Consistent with previous reports, plasma concentrations of branched chain amino acids were lower in PCA compared with SO rats. (33) Similar to our previous report of elevated or unaltered branched chain amino acid concentrations in myotubes during hyperammonemia, (17) branched chain amino acid concentrations were unaltered or increased in the skeletal muscle of PCA rats and lowering ammonia reversed this effect. The intracellular amino acid deficiency sensor GCN2 was activated in the skeletal muscle of PCA rats, even though tissue amino acid concentrations were not reduced in PCA rats. The mechanism of phosphorylation and activation of GCN2 is suggested to be FIG. 5 . In vivo molecular responses to hyperammonemia partially reversed after ammonia-lowering therapy. Representative immunoblots and densitometry of proteins regulating proteostasis in the gastrocnemius muscle of hyperammonemic PCA or SO rats treated with vehicle or ammonia-lowering therapy with r-LOLA for 28 days. (A) Representative immunoblots and densitometry of the expression of myostatin, phospho-AMPK, and its target acetyl coenzyme A carboxylase significantly higher in hyperammonemic PCA rats treated with vehicle compared to SO rats. Ammonia-lowering therapy (r-LOLA) resulted in partial reversal of these perturbations in the PCA rat. (B) Representative immunoblots and densitometry of amino acid deficiency sensor and eIF2a kinase, GCN2, and its target eIF2a show increased expression in hyperammonemic PCA rats treated with vehicle alone compared to the other groups. Ammonia-lowering therapy (r-LOLA) partially reversed the increased phosphorylation of GCN2 and eIF2a in the gastrocnemius muscle of the PCA rat. (C) Representative immunoblots and densitometry showed impaired mTORC1 activation and signaling in PCA rats treated with vehicle compared to SO control rats. Ammonia-lowering therapy partially reversed the molecular perturbations in mTORC1 signaling. (D) Representative immunoblots and densitometry showed increased autophagy markers, LC3 lipidation, and lower P62 expression in the gastrocnemius muscle from hyperammonemic PCA rats treated with vehicle compared with SO control rats. Ammonia-lowering therapy partially reversed these alterations. All data expressed as mean 6 standard deviation from six rats in each group. *P < 0.05, **P < 0.01, ***P < 0.001. r-LOLA orally for 28 days. Abbreviations: ACC, acetyl coenzyme A carboxylase; A.U., arbitrary units; MSTN, myostatin; p-, phosphorylated. mediated by ammonia-induced mitochondrial sequestration of leucine. (17) Even though ammonia lowering did alter plasma amino acids, there was no significant effect on the muscle concentrations of amino acids. Interestingly, despite unaltered muscle amino acid concentrations, GCN2 activation and phosphorylation of eIF2a were partially reversed by ammonia lowering. These observations suggest that reduction in ammonia prevents amino acid use for ammonia detoxification (43) or alters subcellular localization of amino acids with consequent sensing of amino acid adequacy in the cytoplasmic compartment. Whether hyperammonemia or ammonia lowering alters the subcellular localization of GCN2 is currently unknown.
Expression of myostatin, a transforming growth factor beta superfamily member and known inhibitor of muscle mass, was increased in both myotubes and muscle from hyperammonemic PCA rats. These observations were consistent with previous reports by us that hyperammonemia transcriptionally upregulates myostatin. (16) The current study revealed that ammonia-induced up-regulation of myostatin and the consequent decreased protein synthesis are partially reversible in vitro and in vivo. Increased myostatin expression was not fully reversed by ammonia-lowering therapy, which may be due to incomplete reduction in muscle ammonia concentrations or additional ammonia-independent mechanisms of myostatin regulation in vivo. (28) Targeting ammonia alone may also not be adequate to reverse myostatin expression as our in vitro data suggest that after 48 hours of ammonia withdrawal there is nearly complete reversal of the molecular perturbations but that in vivo ammonia reduction does not completely reverse these alterations. Another potential reason for the difference between the in vitro and in vivo responses to ammonia lowering is that there is continued ammonia generation in vivo with impaired disposal due to the underlying liver disease. In this situation, the skeletal muscle remains a major organ for ammonia disposal and consequent molecular responses. Furthermore, our strategy focused on the classical methods to lower gut bacterial ammoniagenesis and the use of LOLA. Although we used 28 days of ammonia-lowering therapy, longer-term and alternative ammonia-disposal treatments may be necessary for complete normalization of muscle ammonia concentrations.
In the present studies, in addition to reversal of GCN2/eIF2a phosphorylation in vivo, mTORC1 signaling was reversed following ammonia withdrawal in myotubes. Similar responses were observed in vivo in the skeletal muscle of PCA rats following 4 weeks of ammonia-lowering therapy. However, the response in vitro to ammonia withdrawal was more robust compared with that in PCA rats. These observations suggest that incomplete reduction in ammonia concentrations in vivo results in only partial reversal of mTORC1 or that other factors besides hyperammonemia contribute to impaired mTORC1 signaling. The downstream molecular consequences of reduced myostatin expression are similar to those reported by us and others. (20, 21) We also observed that expression of autophagy markers was increased in response to hyperammonemia, as reported, (18, 19) and that ammonia withdrawal reversed the elevated autophagy markers (LC3 lipidation, lower p62 expression) both in vitro and in vivo, unlike the incomplete reversal in reduced protein synthesis. These data show that even though ammonia impairs muscle proteostasis, protein synthesis and autophagy markers and flux respond differently to ammonia withdrawal or lowering, and these mechanisms need to be evaluated further.
Our observations are consistent with reports of decreased muscle protein synthesis and a GCN2-dependent hyperammonemic cellular stress response during hyperammonemia. (17, 37) However, there are no studies on muscle proteostasis following ammonia withdrawal to determine if these effects are indeed reversible. This is particularly relevant because following liver transplantation, while ammonia metabolism in the graft is normal, (4) sarcopenia does not reverse, suggesting that ammonia-induced perturbations may not be reversible. However, our data in an in vitro and in vivo model show that ammonia lowering as a strategy to reverse sarcopenia has the potential for rapid clinical translation in patients with liver disease.
We provide evidence that ammonia-lowering strategies in an established preclinical model of sarcopenia in cirrhosis with portosystemic shunting results in partial reversal of muscle loss, molecular perturbations, and recovery of fractional and absolute protein synthesis rates. These data lay the foundation for clinical translational studies in the therapy of muscle loss in liver disease.
